Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (18)

2023

  1. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies

    Journal of Physiology and Biochemistry

  2. Loss of liver function in chronic liver disease: An identity crisis

    Journal of Hepatology, Vol. 78, Núm. 2, pp. 401-414

2022

  1. Bile Processing Protocol for Improved Proteomic Analysis

    Methods in Molecular Biology (Humana Press Inc.), pp. 1-10

  2. Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: Cui bono ?

    Gut

  3. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma

    International Journal of Molecular Medicine, Vol. 49, Núm. 5

  4. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Armcx3 mediates susceptibility to hepatic tumorigenesis promoted by dietary lipotoxicity

    Cancers, Vol. 13, Núm. 5, pp. 1-22

  2. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

  3. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

  4. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

  5. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219

2019

  1. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  2. Messenger RNA therapy for rare genetic metabolic diseases

    Gut, Vol. 68, Núm. 7, pp. 1323-1330

2018

  1. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

    Nature Medicine, Vol. 24, Núm. 12, pp. 1899-1909

2016

  1. Further evidence on the janus-faced nature of the epidermal growth factor receptor: From liver regeneration to hepatocarcinogenesis

    Hepatology, Vol. 63, Núm. 2, pp. 371-374

2015

  1. Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14

    Hepatology, Vol. 61, Núm. 5, pp. 1755-1757

  2. Oxidative Stress Mechanisms in Hepatocarcinogenesis

    STUDIES ON HEPATIC DISORDERS (SPRINGER INTERNATIONAL PUBLISHING AG), pp. 449-477

2014

  1. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes

    Cancer Research, Vol. 74, Núm. 5, pp. 1452-1462